At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Gilteritinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
In Brief
A Phase 2 clinical trial evaluating Gilteritinib for Advanced Solid Tumors and Acute Myeloid Leukemia. Completed, enrolled 9 participants across 7 sites.
Detailed Summary
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Acute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartMay 2016
Primary CompletionJul 2020
TodayJul 2026
First PostedSep 28, 2015
Enrollment StartMay 3, 2016
Primary CompletionJul 28, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.8 years ago
Interventions
Gilteritinibdrug
oral tablet